Adenoid cystic carcinomas (ACCs) are among the most enigmatic of human malignancies. These aggressive salivary gland cancers frequently recur and metastasize despite definitive treatment, with no known effective chemotherapy regimen. Here we determined the ACC mutational landscape and report the exome or whole-genome sequences of 60 ACC tumor-normal pairs. These analyses identified a low exonic somatic mutation rate (0.31 non-silent events per megabase) and wide mutational diversity. Notably, we found mutations in genes encoding chromatin-state regulators, such as SMARCA2, CREBBP and KDM6A, suggesting that there is aberrant epigenetic regulation in ACC oncogenesis. Mutations in genes central to the DNA damage response and protein kinase A signaling also implicate these processes. We observed MYB-NFIB translocations and somatic mutations in MYB-associated genes, solidifying the role of these aberrations as critical events in ACC. Lastly, we identified recurrent mutations in the FGF-IGF-PI3K pathway (30% of tumors) that might represent new avenues for therapy. Collectively, our observations establish a molecular foundation for understanding and exploring new treatments for ACC.
Total number of structural rearrangements NA 17
Total number of genic rearrangements preserving the frame of translation l e t t e r s extensive validation of nearly every candidate somatic mutation identified (2,751 variant calls; Supplementary Fig. 1 ) using targeted resequencing ( Supplementary Fig. 2 and Supplementary Table 1 ). In addition, we also performed FISH analysis to detect the MYB-NFIB translocation ( Supplementary Fig. 3 and Supplementary Table 2) .
We identified a mean of 22 somatic mutations per sample, corresponding to approximately 0.31 non-silent mutations per megabase (Fig. 1) . This rate is quite low compared to most adult solid tumors, such as head and neck squamous cell carcinoma 6, 7 and colon cancer 8 , but similar to hematological malignancies and neuroblastoma [9] [10] [11] . The transition/transversion ratio (Ti/Tv) was 1.1, similar to that found in some carcinogen-driven malignancies 6, 7, 12 but unlike the rates detected in most described cancer types 13 . The somatic mutation frequency correlated with solid histology (Wilcoxon ranksum test P = 4.0 × 10 −2 ), and MYB translocations occurred in 57% of samples (34/60) .
We validated 710 distinct nonsynonymous mutations across 643 genes (1-36 mutations per tumor; Fig. 1a, Supplementary Fig. 4 and Supplementary Table 3) , with substantial mutational heterogeneity observed across tumors (Figs. 1b and 2) . We employed CHASM, a widely used approach for distinguishing driver and passenger mutations 14 , to identify multiple potential driver mutations, including ones in PIK3CA, TP53, PTEN, SMARCA2, KDM6A and CREBBP (Supplementary Tables 4 and 5) . Analysis of these genes with driver mutations showed marked enrichment in pathways involved in chromatin remodeling, DNA damage response, MYB-MYC, protein npg l e t t e r s kinase A (PKA) and phosphatidyl inositol 3-kinase (PI3K) signaling ( Fig. 1c-e) . For example, despite low overall mutation frequency, 35% of ACC tumors were mutated in chromatin regulators. These data suggest that the ACC mutational landscape is characterized by combinations of MYB pathway alterations and mutations in specific biological processes (Fig. 2) . Notably, a small subset of tumors (n = 8) was observed with no CHASM-designated driver mutations. It is possible that some mutations in these tumors are drivers not called by CHASM or that other non-exonic alterations are important. We used exome and genome sequencing data to characterize the ACC copy number landscape. We analyzed somatic copy number variations (CNVs) using ExomeCNV 15 and found high concordance with a subset (n = 12) that additionally underwent array-based analysis. GISTIC2.0 (ref. 16) identified recurrent high-level losses at 6q24, 12q13 and 14q ( Fig. 3a and Supplementary Table 6 ) 5 . Samples with 14q loss were more likely to have solid histology (Fisher's exact test P = 2.0 × 10 −4 ), whereas samples with 6q24 loss were enriched for advanced tumor stage (P = 4.0 × 10 −2 ). Expression array analysis on 23 ACC tumors found no distinct subgroups (Supplementary Fig. 5 ). Genes harboring driver mutations were confirmed to be expressed in ACC tumors (Supplementary Table 7) .
Whole-genome paired-end sequencing identified numerous structural variations ( Fig. 3b and Supplementary Table 8) , and the existence of 17 structural variations across 5 samples was confirmed using PCR ( Supplementary Fig. 6 and Supplementary Table 9 ).
When also taking into account FISH data, MYB translocations were the only recurrent structural variations detected. However, we cannot exclude the possibility that there are less common recurrent translocations 17 . Notably, one sample harbored a tandem duplication within FGFR2. Similar alterations comprising dimerized, constitutively active variants have been described in hematological malignancies 18 . We did not detect a fusion transcript from this tumor using RT-PCR, but this does not rule out an alternative transcript configuration. Larger numbers of tumors will need to be analyzed to further characterize the incidence of this alteration and its impact. The remaining variants were not predicted to be in frame. Collectively, few CNVs or structural variations were found across the cohort, demonstrating the relatively 'quiet' nature of the ACC genome. Thus, our data indicate that the major structural variations in ACC are MYB translocations and recurrent deletions on 6q24, 12q13 and 14q.
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npg l e t t e r s including in SMARCA2 (5%), as well as single mutations in SMARCE1 (2%), ARID1A (2%) and ATRX (2%). SMARC family mutations contribute to the development of both cancers and genetic diseases [21] [22] [23] [24] [25] . SMARCA2 encodes a core catalytic subunit of the SWI/SNF complex, which is involved in regulating gene transcription 26 . All SMARCA2 mutations were clustered within the region encoding the helicase C domain (p.Thr1126Ile, p.Gly1132Val and p.Gly1164Trp). Mutated helicases have been shown to increase cancer susceptibility, likely by disturbing core repair mechanisms 27 . Similarly, we identified probable loss of function in SMARCE1 (2%), another SWI/SNF complex gene, identifying a high-mobility-group (HMG) box domain alteration (p.Tyr73Cys) that presumably affects DNA binding 28 . Additional recurrent mutations included ones in CREBBP (7%), a histone acetyltransferase that enables transcription across multiple critical signaling pathways 24, 25, 29 . The majority of CREBBP mutations clustered in the region encoding the critical KAT11 histone acetylation domain (p.Arg1446Cys, p.Ile1453Asn and p.Trp1472Ser) 30 . We also observed numerous missense mutations in KDM6A (7%), also known as UTX, which encodes a histone demethylase 31 . The functional impact of these KDM6A mutations was evaluated via a well-characterized assay for trimethylation at lysine 27 of histone H3 (H3K27me3). We observed abrogation of demethylase activity in cells overexpressing mutant KDM6A but not in those overexpressing wild-type KDM6A (Fig. 5a,b) . Moreover, whereas wild-type KDM6A suppressed growth, mutants either lost the ability to suppress growth or, in some cases, augmented it (dominant phenotype).
Other related mutations included ones in genes encoding proteins with histone acetyltransferase or deacetylase activity (EP300, ARID4B, ARID5B and BRD1) and histone methyltransferase or demethylase activity (FTSJD1 and MLL3), as well as in histones themselves (HIST1H2AL and HIST1H1E). EP300 binds CREBBP as a transcriptional coactivator that regulates cell proliferation and differentiation 32 and harbors a splice-site mutation affecting its KAT11 histone acetylation domain (p.Gly1429?). HIST1H2AL encodes a core component of the nucleosome, and HIST1H1E encodes a protein that is known to link histones for compaction into higher-order structures. Notably, histone gene mutations have been implicated in cancers such as pediatric gliomas 8, 33, 34 . Although mutations in our study were observed to affect known protein domains (p.Arg18Leu in core histone H2A, H2B, H3 and H4 and p.Lys75Asn in linker histone H1 and H5 domains), further investigation will be necessary to determine the functional impact of these alterations. Overall, a multitude of chromatin genes were involved, suggesting that disparate means of chromatin dysregulation may promote ACC development through convergent networks. Given the emerging importance of agents targeting epigenetic regulation in other disorders 35, 36 , similar treatments for patients with ACC with chromatin derangements might hold promise.
We observed a second group of mutations in genes involved in the DNA damage response (q = 5.6 × 10 −3 ; Fig. 4b ). In TP53 (5% incidence), one missense (p.Pro151Ser) and two nonsense (p.Arg213* and p.Arg342*) variants were identified that affect the central binding a   b   4332  000540  002282  10_5342  11_3318  065103  002128  09_4178  007441  002238  142990  671204  2000120  2453  000410  111097  001346  352  000380  128229  09_12352  118135  122891  6112  131169  002020  000505  065115  6277  000609  3492  80872  06_2532  10_5283  9534  001781  000236  11_6165  07_16582  2000756  36773720  11_3089  05_6986  000705  990149  000479  007097  001739  007136  980452  09_4615  11_17815  006536  148632  002039  2000136  001947  002237 (Fig. 1e) . Similarly, UHRF1, encoding a ubiquitin ligase involved in the TP53-dependent DNA damage checkpoint 37 , was altered in 8% of cases (two mutations and three homozygous deletions). TXNIP, encoding a protein frequently repressed in cancers 38, 39 , was noted to have a frameshift insertion affecting its arrestin domain (p.Leu129fs). We also identified tumors that harbored two missense mutations within a particular gene (ATM, BRCA1 or DCLRE1A, a DNA cross-link repair gene). We moreover found markedly decreased expression of key TP53 transcriptional targets specifically in tumors with TP53 pathway alterations (binomial test P = 1.0 × 10 −4 ; Fig. 5c ).
Previous work has implicated MYB as an ACC fusion oncogene with NFIB via a t(6;9) translocation 40 (Fig. 4c) . Indeed, we verified that 57% of our cohort had the MYB-NFIB translocation by FISH analysis. We extended this initial finding and observed further MYB pathway dysregulation, with alterations found in an additional 8% of cases. Specifically, splice-site and coding mutations involving exon 10 of MYB were seen, which potentially disrupt its leucine-rich negative regulatory domain 40 and trigger constitutive activation. Five additional MYB homozygous deletions were identified in CNV analysis (4 of 5 tumors were positive for the MYB-NFIB translocation), although these deletions may be secondary alterations occurring around the translocation. Other mutations identified in the MYB pathway included ones present in MYCBP2, MGA and MCM4. In NFIB, we observed two truncating mutations affecting the CTF/NFI transcription modulation domains (p.Tyr249* and p.Pro390fs), in addition to four homozygous deletions (all tumors were positive for the MYB-NFIB translocation). Our data highlight MYB as an active oncogenic partner in fusion transcripts in ACC but also suggest a separate role for NFIB, given the presence of mutations specific to this gene.
Multiple genes involved in the PKA pathway were found to be mutated (27% incidence; q = 4.2 × 10 −3 ). We identified recurrent mutations in RYR3 (7%) and RYR2 (2%), both of which encode tetrameric intracellular calcium channels implicated in breast cancer progression 41, 42 . Mutations were also observed in PKA pathway-associated genes that are known or potential tumor suppressors, including in tyrosine phosphatases (PTPRG, PTPRH, PTPRJ and PTPRK). Nonsense (PTPRG and PTPRH) and frameshift (PTPRK) mutations abrogated the phosphatase domains of the encoded proteins (p.Glu736*, p.Trp602* and p.Leu457fs, respectively), and an additional four samples had homozygous deletions of PTPRK. PKA signaling components are known to facilitate CREBBP recruitment via calcium influx 43 and CREB phosphorylation, which regulates multiple critical developmental processes involved in tumorigenesis 24, 44 .
Mutations in genes important in the fibroblast growth factor (FGF)-insulin-like growth factor (IGF)-PI3K pathway were also identified in 30% of our cohort (q = 2.4 × 10 −2 ; Fig. 4d ). Three tumors harbored separate missense mutations in PIK3CA (Fig. 1e) . Another tumor had two mutations in PTEN affecting the catalytic domain (p.Arg130fs and p.Lys144Gln). All five lesions occurred in COSMIC v61 (Catalogue of Somatic Mutations in Cancer) hotspots 45 . FOXO3 (ref. 46 ) was also altered in 7% of tumors. We further identified mutations in receptor kinase and PI3K-associated genes, including in FGF16, FGFR4, IGFBP2 and ILR17RD. FGF and IGF proteins are potent, oncogenic PI3K activators 47, 48 , whereas IL17RD seems to be a PI3K inhibitor through its interaction with FGFR 49 . The samples with PI3K-associated insults all had solid histology, considered the most aggressive ACC variant (Fisher's exact test P < 1.6 × 10 −3 ). We further evaluated samples with altered PI3K using immunohistochemistry to detect phosphorylated AKT and PRAS40. Functional activation of the PI3K pathway was observed in all ACC tumors harboring PIK3CA or PTEN mutations but not in tumors with wild-type forms of these genes ( Fig. 5d and Supplementary Fig. 7) . This finding is supported by the presence of significantly enriched PI3K signatures in ACC tumors with mutant PI3K identified via GSEA (Gene Set npg l e t t e r s Enrichment Analysis) (P < 1.0 × 10 −3 ; Supplementary Fig. 8a ). Taken together, these findings delineate a previously undescribed subset of patients with ACC who we hypothesize might benefit from agents targeting this pathway 50 . Despite not meeting significance by CHASM analysis, alterations were observed in the Notch signaling pathway in 13% of samples (Fig. 4e) . In addition to recurrent NOTCH1 (5% incidence, including three missense and one nonsense) and FOXP2 (3%) mutations, predicted functional mutations were found in DTX4, FBXW7 and CNTN6. FBXW7 (p.Arg465His alteration identified) is a tumor suppressor that targets c-myc and NOTCH1 for degradation 51 . NOTCH1 has a dual role in cancer, depending on cellular context, as either an oncogene or a tumor suppressor 6,7,52-55 . Analysis of ACC samples with altered NOTCH1 using GSEA 56 showed a trend toward enrichment of Notch signaling (Supplementary Fig. 8b ). These alterations require further characterization but may have therapeutic implications 57 .
Notably, we observed mutations in various genes involved in cell metabolism processes. Of particular interest are recurrent alterations in HSPG2 (7%), which encodes a basement membrane-based proteoglycan (perlecan) known to modulate tumorigenic growth factors, including FGF. FGF signaling promotes mitogenesis and angiogenesis 58 , whereas deletion of perlecan heparan sulfate domains has been shown to impair tumorigenesis [59] [60] [61] . ACC produces high perlecan levels within its pseudocystic cribiform structures 62, 63 , and maximum perlecan synthesis occurs during the tumor's proliferative phase 64 .
Additionally, we identified a hotspot IDH1 mutation affecting the encoded catalytic domain (p.Arg132His) 33, [65] [66] [67] .
ACC is unique in its propensity for perineural invasion and distant metastasis. We noted numerous mutations in genes encoding cell adhesion molecules (29% incidence). We found mutations affecting the active domains of factors responsible for neuronal axon guidance cues, including in NTNG1, SEMA3G and SEMA5A. Netrins and semaphorins are implicated in neuronal invasion 68 and metastasis 69 . Additionally, mutations in protocadherin genes were observed, including truncating mutations in FAT3 and FAT4. FAT4 has been hypothesized to be a tumor suppressor in gastric adenocarcinoma 70 . We examined FAT4 through RNA interference (RNAi)-mediated knockdown in human salivary cells (HSG, HSY and HTB-41 cells) as well as in fibroblasts (HFF-1 cells) ( Fig. 5e and Supplementary Fig. 9 ). Significant increases in growth occurred after FAT4 knockdown but not in controls.
In summary, we report a large-scale ACC analysis and highlight new ACC driver mutations within corresponding pathways. Convergent alterations include pathway derangements involving chromatin remodeling, DNA damage response, MYB-MYC and tyrosine kinase signaling (Fig. 4) . Our discovery of genomic alterations in targetable pathways suggests potential avenues for novel treatments to address a typically chemoresistant malignancy. Verified ACC cell lines 71, 72 are needed to further substantiate the clinical usefulness of the mutations identified here. In total, our data provide insights into the genetic framework underlying ACC oncogenesis and establish a foundation for identifying new therapeutic strategies. . Experiments were performed in triplicate. Two RNAi constructs were used for FAT4 knockdown (KD). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, NS, not significant (ANOVA). Error bars, ± 1 s.e.m.
npg l e t t e r s
Pathway analyses for enrichment were performed using IPA (Winter Release 2012, Ingenuity Systems), DAVID v6.7 (Database for Annotation, Visualization and Integrated Discovery) 94 and hypergeometric distribution, with potential CHASM-identified drivers used as input. Enriched gene sets reflecting Gene Ontology 95 biological processes, Kyoto Encyclopedia of Genes and Genomes (KEGG, Release 64.0) and Biocarta pathways were corrected for multiple-hypothesis testing using the Bonferroni method. Aberrant signaling pathways (Fig. 4) were constructed referencing IPA and Pathway Commons 38 . Expression data were analyzed using GSEA v2.0. 10 (ref. 56) . Functional consequences were also evaluated using the Memorial Sloan-Kettering Cancer Center cBioPortal for Cancer Genomics 96, 97 . FAT4 knockdown, transfection and viral transduction. FAT4 knockdown was performed using small interfering RNA (siRNA) or short hairpin RNA (shRNA) (Dharmacon). siRNAs were transfected into cells in antibiotic-free medium using Lipofectamine RNAiMAX (Invitrogen), medium was changed after 6 h and cells were harvested after 48 h. pGIPZ shRNAs were transfected into 293T cells, along with plasmids encoding packaging and envelope proteins. Viruses were harvested from cell culture supernatant at 48, 72 and 96 h after transfection. Cells were transduced with 8 µg/ml polybrene. Two independent RNAi sequences were used for knockdown. The fold change of relative knockdown was normalized to mRNA levels of respective controls.
KDM6A mutagenesis and overexpression. Plasmid encoding Flag-tagged KDM6A was obtained (AddGene, 17438), and site-directed mutagenesis was performed with QuikChange II XL (Stratagene). We transfected 293T and COS7 cells using FuGene HD (Promega).
Immunofluorescence. COS7 cells were plated on poly-d-lysine coverslips (BD Biosciences) and transfected with plasmids encoding wild-type or mutant Flag-tagged KDM6A. After a 36-h incubation, cells were fixed in 4% paraformaldehyde in PBS, permeabilized in 0.5% Triton X-100 in PBS and blocked in 10% FBS. Primary antibodies included those to Flag (Sigma, F3165; 1:50 dilution) and H3K27me3 (Millipore, 07-449; 1:50 dilution). Secondary antibodies included Alexa Fluor 488-conjugated antibody to mouse IgG and Alexa Fluor 568-conjugated antibody to rabbit IgG (Molecular Probes; 1:200 dilutions). Images were acquired using an SP5 confocal microscope (Leica).
Growth curves. Growth curve assays were performed in triplicate, and cell numbers were quantified using the Vi-Cell XR Cell Viability Analyzer (Beckman Coulter) or in real time in quadruplicate with the xCELLigence System (Roche). xCELLigence plates were seeded with 5,000 or 20,000 cells per well. Growth was reported as the cell index, a measure of impedance reflecting the number of viable, adherent cells.
TP53 signaling pathway PCR array.
Approximately 200 ng of RNA extracted from fresh-frozen tissue was used to generate cDNA with SuperScript III (Invitrogen). Gene expression was quantified using the RT 2 Profiler PCR Array Human p53 Signaling Pathway (SABioscience). Reactions were performed using a Mastercycler ep Realplex 4s and Realplex software (Eppendorf). The 2 −∆∆C T method was used to calculate ∆∆C T values. In all tissue-specific comparisons, individual gene expression levels in tumor specimens were compared with those in normal salivary tissue. Comparisons were made between TP53 pathway wild-type and TP53 pathway altered samples. Expression levels of all 84 TP53 target genes were normalized against the average levels of the 2 most stably expressed reference genes (GAPDH and HPRT1). Gene expression was considered below the limit of detection if the C T value was 35.0 or greater.
